GSA Capital Partners LLP Increases Stake in Johnson & Johnson (NYSE:JNJ)

GSA Capital Partners LLP boosted its position in Johnson & Johnson (NYSE:JNJ) by 149.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,268 shares of the company’s stock after purchasing an additional 16,951 shares during the quarter. Johnson & Johnson comprises 0.3% of GSA Capital Partners LLP’s investment portfolio, making the stock its 25th biggest position. GSA Capital Partners LLP’s holdings in Johnson & Johnson were worth $3,675,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Harding Loevner LP purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in shares of Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares in the last quarter. IHT Wealth Management LLC raised its position in shares of Johnson & Johnson by 46.4% during the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after buying an additional 3,467 shares in the last quarter. Mountain Capital Investment Advisors Inc purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $124,000. Finally, Shine Investment Advisory Services Inc. purchased a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $177,000. Institutional investors and hedge funds own 67.23% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several research firms have recently weighed in on JNJ. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $146.00 price objective on the stock in a research report on Thursday. Vetr cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $124.55 price objective on the stock. in a research report on Thursday. TheStreet cut shares of Johnson & Johnson from an “a” rating to a “c+” rating in a research report on Monday, March 26th. Jefferies Group set a $161.00 price objective on shares of Johnson & Johnson and gave the company a “buy” rating in a research report on Friday, March 23rd. Finally, Citigroup lowered their price objective on shares of Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 27th. Five equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the stock. Johnson & Johnson currently has an average rating of “Hold” and an average target price of $144.58.

In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the sale, the vice president now owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.22% of the stock is owned by company insiders.

Johnson & Johnson stock traded down $2.61 during trading hours on Friday, reaching $128.10. The stock had a trading volume of 6,399,310 shares, compared to its average volume of 7,081,583. The firm has a market cap of $350,682.16, a PE ratio of 17.55, a price-to-earnings-growth ratio of 2.08 and a beta of 0.74. Johnson & Johnson has a 52 week low of $120.95 and a 52 week high of $148.32. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.02. The business had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The company’s revenue was up 11.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.58 EPS. sell-side analysts expect that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “GSA Capital Partners LLP Increases Stake in Johnson & Johnson (NYSE:JNJ)” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/gsa-capital-partners-llp-purchases-16951-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply